Allogeneic Hematopoietic Cell Transplantation with Full-Intensity Conditioning for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1998-2006

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 8, 2011, Pages 1187-1195

  Doney, Kristine ^a,b   Gooley, Ted A ^a,b   Deeg, H Joachim ^a,b   Flowers, Mary E D ^a,b   Storb, Rainer ^a,b   Appelbaum, Frederick R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Hematopoietic cell transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; COHORT ANALYSIS; ENGRAFTMENT; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; QUALITY OF LIFE; REMISSION;

ADOLESCENT; ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79960279215     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.12.699     Document Type: Article

References (40)

1. Larson R.A. Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant 2009, 15(Suppl):11-16.
2. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008, 111:1827-1833.
3. Goldstone A.H. Transplants in adult ALL? Allo for everyone (review). Biol Blood Marrow Transplant 2009, 15(Suppl):7-10.
4. Bruggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116-1123.
5. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? (review). Leukemia 2007, 21:622-626.
6. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
7. Doney K., Hägglund H., Leisenring W., et al. Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2003, 9:472-481.
8. Borowitz M.J., Shuster J., Carroll A.J., et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. Blood 1997, 89:3960-3966.
9. Pullarkat V., Slovak M.L., Kopecky K.J., et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group study SWOG-9400. Blood 2008, 111:2563-2572.
10. McCune J.S., Batchelder A., Guthrie K.A., et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther 2009, 85:615-622.
11. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986, 314:729-735.
12. Nash R.A., Etzioni R., Storb R., et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995, 85:3746-3753.
13. Nash R.A., Pineiro L.A., Storb R., et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996, 88:3634-3641.
14. Przepiorka D., Weisdorf D., Martin P., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
15. Vigorito A.C., Campregher P.V., Storer B.E., et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009, 114:702-708.
16. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of Chemotherapeutic Agents 1949, 191. Columbia University Press, New York, NY. C.M. Macleod (Ed.).
17. Boeckh M., Ljungman P. How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
18. Ruutu T., Eriksson B., Remes K., et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002, 100:1977-1983.
19. Tay J., Tinmouth A., Fergusson D., et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation (review). Biol Blood Marrow Transplant 2007, 13:206-217.
20. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
21. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
22. Cox D.R. Regression models and life tables. J R Stat Soc B 1972, 34:187-220.
23. Martin P.J., McDonald G.B., Sanders J.E., et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004, 10:320-327.
24. Mickelson E., Petersdorf E.W. Histocompatibility. Thomas' Hematopoietic Cell Transplantation 2009, 145-162. Wiley-Blackwell, Oxford, UK. F.R. Appelbaum, S.J. Forman, R.S. Negrin (Eds.).
25. Wassmann B., Pfeifer H., Goekbuget N., et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006, 108:1469-1477.
26. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460-466.
27. Carpenter P.A., Snyder D.S., Flowers M.E.D., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791-2793.
28. Foy P.C., van Burik J.A., Weisdorf D.J. Galactomannan antigen enzymelinked immunosorbent assay for diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:440-443.
29. Jamieson C.H., Amylon M.D., Wong R.M., et al. Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience. Exp Hematol 2003, 31:981-986.
30. Marks D.I., Forman S.J., Blume K.G., et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 2006, 12:438-453.
31. Kiehl M.G., Kraut L., Schwerdtfeger R., et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004, 22:2816-2825.
32. Laport G.G., Alvarnas J.C., Palmer J.M., et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 2008, 112:903-909.
33. Marks D.I., Wang T., Perez W.S., et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010, 116:366-374.
34. Pagel J.M., Appelbaum F.R., Eary J.F., et al. 131I anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006, 107:2184-2191.
35. Nordlander A., Mattsson J., Ringden O., et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2004, 10:195-203.
36. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
37. Appelbaum F.R. Graft versus leukemia (GvL) in the therapy of acute lymphoblastic leukemia (ALL). Leukemia 1997, 11:S15-S17.
38. Passweg J.R., Tiberghien P., Cahn J.-Y., et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998, 21:153-158.
39. Uzunel M., Mattsson J., Jaksch M., et al. The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 2001, 98:1982-1984.
40. Porter D.L., Alyea E.P., Antin J.H., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:1467-1503.